bone morphogenetic protein (bmp)

DMH-1 is a potent and selective Bone Morphogenetic Protein (BMP) inhibitor.

SY-LB-57 is a highly effective agonist of bone morphogenetic protein (BMP) receptor signaling, suitable for studies of conditions such as bone fractures and pulmonary arterial hypertension [1].

BMP signaling agonist sb4 (SB 4) is an agonist of benzoxazole bone morphogenetic protein (BMP) signaling (EC50 :74 nM)

BMT-124110 Formate is a selective AAK1 inhibitor (IC50: 0.9 nM) with anti-injury sensory activity.BMT-124110 Formate inhibits the BMP-2-inducible protein kinase BIKE with an IC50: 17 nM.BMT-124110 Formate inhibits the cell-cycle protein G-related BMT-124110 Formate inhibits the cell cycle protein G-associated kinase GAK with an IC50:99 nM.

Chromenone 1 is a potent potentiator of osteogenic bone morphogenetic protein (BMP). Chromenone 1 induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs.

Smurf1-IN-5 (Compound cpd-6) is an inhibitor of the SMAD ubiquitin regulatory factor (SMURF1). It reduces the ubiquitination of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, thereby enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 holds promise for research in pulmonary arterial hypertension (PAH).

DMH2 is an antagonist of bone morphogenetic protein (BMP) type I receptor. It acts by decreasing growth and inducing cell death of lung cancer cell lines.

LDN-193189 2HCl (DM-3189 2HCl) is a selective BMP signaling inhibitor that inhibits ALK1,ALK2,ALK3 and ALK6, showing IC50s of 0.8 nM, 0.8 nM, 5.3 nM, and 16.7 nM, respectively, in kinase assays.LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively. LDN-193189 2HCl inhibited the transcriptional activity of BMP type I receptors ALK2 and ALK3 in C2C12 cells, with IC50s of 5 nM and 30 nM, respectively, and was 200-fold more selective for BMP than for TGF-β.

SM1-71 is a potent multi-targeted acrylamide-modified TAK1 inhibitor that inhibits MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2.SM1-71 can be used as a kinase probe with anticancer activity and inhibits the proliferation of various cancer cell lines.

SY-LB-35, a potent bone morphogenetic protein (BMP) receptor agonist, significantly enhances cell number and viability in the C2C12 myoblast cell line. It promotes cell cycle progression, particularly towards the S and G2/M phases. Additionally, SY-LB-35 activates both canonical Smad and non-canonical intracellular signaling pathways, including PI3K/Akt, ERK, p38, and JNK [1].

SJ000063181 is a potent activator of BMP signaling, exhibiting an EC50 of ≤1 μM. It serves as a valuable chemical probe for BMP signaling analysis, owing to its ability to penetrate zebrafish embryos.

ER 50891 quarterhydrate is a potent RARα (retinoic acid receptor α) antagonist that significantly reduces the inhibitory effects of ATRA (all-trans retinoic acid) on BMP 2 (bone morphogenetic protein 2)-induced osteoblastogenesis [1].

BMP agonist 2 has up-regulated bone morphogenetic protein BMP-2 expression activity in vivo and anti-osteoporosis effects, and also has ameliorated the symptoms of osteoporosis in SAMP6 mice.BMP agonist 2 is an osteoinductive cytokine that promotes the production of bone tissue, and can be used in the study of senile osteoporosis (SOP).